HIND: Vyome Holdings Inc Growth-Adjusted Market Cap to Net Income

Brandmark of Vyome Holdings Inc (HIND)

Following the asset restructuring and adaptation of operational plans by Vyome Holdings Inc management, the valuation and growth balance indicator captures current market sentiment, where the 0.00 metric confirms the value level. Looking ahead, growth will be driven by biologicals for dermatological pathologies, the integration of ReShape Lifesciences, and the launch of weight loss products, which will create a sustainable cash flow.

HIND ReShape Lifesciences: Price/Earnings to Growth Ratio in the range 08/16/2025 - 11/17/2026

Metric breakdowns and analytics for ReShape Lifesciences (HIND)

General company analysis:HIND - Vyome Holdings Inc
Signature product of Vyome Holdings Inc.

This indicator compares market capitalization with earnings dynamics, determining the asset's fundamental value through the ratio of P/E to business expansion rates. In the context of Vyome Holdings Inc (HIND), the PEG ratio allows for an assessment of whether the premium for dermatological drug patents is justified, signaling undervaluation at values below one prior to the completion of key R&D stages.

Who Vyome Holdings Inc competes with

ARGX (Argenx) - Growth-Adjusted Payback Ratio|PEG Multiple BNTX (biontech.de)|Growth-Adjusted Market Cap to Net Income Abivax S.A. (ABVX)|ADMA - Price/Earnings to Growth Ratio|Protagonist Therapeutics, Inc. (PTGX) - Price/Earnings to Growth Multiple|Immunovant Therapeutics (IMVT) - Price/Earnings to Growth Ratio|Price/Earnings to Growth Multiple Kiniksa Pharmaceuticals|Price/Earnings to Growth Multiple GRFS|PEG Multiple adaptivebiotech.com|Price/Earnings to Growth Ratio Celldex (CLDX)|Aurinia Pharmaceuticals Inc. - Growth-Adjusted P/E Ratio|PEG Multiple BCRX (biocryst.com)|Vera Therapeutics, Inc. (VERA) - Price to Earnings Adjusted for Growth Rate|Dianthus Therapeutics, Inc. - PEG Multiple|Market Cap to Earnings and Growth Ratio PHVS|ABCL: PEG Multiple|Price to Earnings Adjusted for Growth Rate Tourmaline Corp (TRML)|PGEN (precigen.com) - PEG Multiple|PEG Multiple Pharming Corp|Price/Earnings to Growth Multiple NKTR (Nektar)|UPB (Upstream Bio Inc) - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Zenas Bio ZBIO|IMNM: Growth-Adjusted P/E Ratio|GOSS - Price/Earnings to Growth Ratio|Growth-Adjusted Market Cap to Net Income KalVista Pharmaceuticals KALV|Septerna (SEPN) - Price/Earnings to Growth Ratio|pieris.com - Growth-Adjusted Payback Ratio|SVRA (Savara Inc) - PEG Multiple|RIGL: Growth-Adjusted Payback Ratio|PEG Multiple ANAB|ATXS (Astria Pharma) - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio enGene Holdings Inc. ENGN|PEG Multiple RAPT Therapeutics Inc. RAPT|Aerovate Therapeutics - PEG Multiple|Price to Earnings Adjusted for Growth Rate Aclaris Therapeutics Inc.|Kyverna (KYTX) - Price/Earnings to Growth Ratio|Price to Earnings Adjusted for Growth Rate Tiziana Life Sciences (TLSA)|Price/Earnings to Growth Ratio Cabaletta Bio Inc.|Ventyx Biosciences (VTYX) - Growth-Adjusted Market Cap to Net Income|PEG Multiple THTX|PEG Multiple Avalo Therapeutics Inc. (AVTX)|PEG Multiple ELDN (eledon.com)|AGEN - Price/Earnings to Growth Multiple|CLYM: Price/Earnings to Growth Multiple|ZURA (Zura Bio Limited) - Growth-Adjusted P/E Ratio|ATYR: PEG Multiple|Adagene (ADAG) - PEG Multiple|IMA (ikenaoncology.com) - PEG Multiple|shattucklabs.com (STTK) - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio Equillium Inc (EQ)|Connect Pharma - Growth-Adjusted P/E Ratio|Price/Earnings to Growth Ratio Immunic, Inc. IMUX|ATRA - Price/Earnings to Growth Multiple|IFRX - Price/Earnings to Growth Ratio|XFOR: Price/Earnings to Growth Ratio|ACET: PEG Multiple|Celularity Corp (CELU) - PEG Multiple|Price/Earnings to Growth Ratio INmune Bio|Barinthus Biotherapeutics plc (BRNS) - Growth-Adjusted Market Cap to Net Income|PEG Multiple KZR|SABS: Market Cap to Earnings and Growth Ratio|PEG Multiple AKTX (Akari Therapeutics, Plc)|ENLV (Enlivex Therapeutics, Ltd.) - Market Cap to Earnings and Growth Ratio|QTTB: Price/Earnings to Growth Multiple|GOVX - PEG Multiple|Edesa Biotech Corp (EDSA) - Price/Earnings to Growth Ratio|IBIO - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio carismatx.com|XTLB: Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Bolt Biotherapeutics Inc. (BOLT)|HCWB (HCW Biologics) - Growth-Adjusted Payback Ratio|Aptevo Therapeutics - Price/Earnings to Growth Multiple|PEG Multiple AIM ImmunoTech Inc. AIM|Aditxt Inc. - PEG Multiple|Growth-Adjusted Payback Ratio GRI (GRI Bio, Inc.)|XORTX Therapeutics Inc (XRTX) - Price/Earnings to Growth Ratio|Revelation Bio (REVB) - PEG Multiple|INDP (Indaptus Corp) - PEG Multiple|SCNI: Growth-Adjusted Payback Ratio|PEG Multiple CALI|Price/Earnings to Growth Multiple Affimed N.V. AFMD|Price/Earnings to Growth Ratio Allakos ALLK|HOOK: Growth-Adjusted P/E Ratio|IGMS - Price/Earnings to Growth Ratio|Growth-Adjusted Market Cap to Net Income iTeos Therapeutics ITOS|Ocean Biomedical (OCEA) - Price/Earnings to Growth Ratio|tcbiopharm.com (TCBP) - PEG Multiple|THRD (Third Harmonic Bio Inc.) - PEG Multiple